Current Oncology Reports

, Volume 7, Issue 6, pp 399–405 | Cite as

New agents in the treatment of childhood leukemias and myelodysplastic syndromes

  • Seth J. Corey
Article
  • 47 Downloads

Abstract

Relapsed or refractory leukemia remains the most common therapeutic problem in pediatric oncology. Particularly challenging is the patient who has recurrence following a stem cell transplant. Insights into the molecular pathogenesis of the leukemias have produced an array of new agents. These new agents will be more selective in hitting their targets, and so their use will be more narrowly defined than with classical cytotoxic drugs. These new agents include all-trans retinoic acid, gemtuzumab ozogamicin, imatinib mesylate, rituximab, and a bevy of signal transduction inhibitors and therapeutic monoclonal antibodies. Other new agents, such as liposomal daunorubicin, PEG-asparaginase, or clofarabine, represent chemical modifications of established antileukemic drugs. Increasingly, molecular profiling will be used to guide the development and application of new drugs.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535–1548.PubMedCrossRefGoogle Scholar
  2. 2.
    Meshinchi S, Smith FO, Arceci RJ: Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Curr Oncol Rep 2003, 5:489–497.PubMedCrossRefGoogle Scholar
  3. 3.
    Wells RJ, Adams MT, Alonzo TA, et al.: Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children’s Cancer Group Study 2951. J Clin Oncol 2003, 21:2940–2947. Demonstrates excellent salvage rate in children and provides a gold standard for alternative regimens.PubMedCrossRefGoogle Scholar
  4. 4.
    Yusuf U, Frangoul HA, Gooley TA, et al.: Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004, 33:805–814.PubMedCrossRefGoogle Scholar
  5. 5.
    Pulsipher MA: Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer 2004, 43:523–533.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheson BD, Bennett JM, Kopecky KJ, et al.: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642–4649. Provides a critical analysis and prescription for the design and interpretation of clinical trials in leukemia.PubMedCrossRefGoogle Scholar
  7. 7.
    List AF, Kopecky KJ, Willman CL, et al.: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001, 98:3212–3220.PubMedCrossRefGoogle Scholar
  8. 8.
    Greenberg PL, Lee SJ, Advani R, et al.: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004, 22:1078–1086.PubMedCrossRefGoogle Scholar
  9. 9.
    Liu Yin JA, Wheatley K, Rees JK, Burnett AK: Comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/ relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001, 113:713–726.PubMedCrossRefGoogle Scholar
  10. 10.
    Krance RA, Hurwitz CA, Head DR, Raimondi SC, et al.: Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001, 19:2804–2811.PubMedGoogle Scholar
  11. 11.
    Gordon MS, Young ML, Tallman MS, et al.: Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leuk Res 2000, 24:871–875.PubMedCrossRefGoogle Scholar
  12. 12.
    Kantarjian H, Gandhi V, Cortes J, et al.: Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003, 102:2379–2386.PubMedCrossRefGoogle Scholar
  13. 13.
    Jeha S, Gandhi V, Chan KW, et al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784–789. Phase II study of clofarabine that provided the basis for its recent approval.PubMedCrossRefGoogle Scholar
  14. 14.
    Berg SL, Blaney SM, Devidas M, et al.: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J Clin Oncol 2005, 23:3376–3382.PubMedCrossRefGoogle Scholar
  15. 15.
    Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042.PubMedCrossRefGoogle Scholar
  16. 16.
    Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645–652.PubMedCrossRefGoogle Scholar
  17. 17.
    Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037. The first report of efficacy of imatinib mesylate, heralding the signal transduction inhibitor therapeutic era.PubMedCrossRefGoogle Scholar
  18. 18.
    Thomas DA, Faderl S, Cortes J, O’Brien S, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.PubMedCrossRefGoogle Scholar
  19. 19.
    Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399–401.PubMedCrossRefGoogle Scholar
  20. 20.
    Richardson PG, Barlogie B, Berenson J, et al.: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609–2617. The clinical study that facilitated the approval of bortezomib and acceptance of proteosomal inhibiton as a therapeutic target.PubMedCrossRefGoogle Scholar
  21. 21.
    Yu C, Rahmani M, Conrad D, et al.: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003, 102:3765–3774.PubMedCrossRefGoogle Scholar
  22. 22.
    List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549–557. A simple study demonstrating efficacy in complex patients with MDS.PubMedCrossRefGoogle Scholar
  23. 23.
    Shen ZX, Chen GQ, Ni JH, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354–3360.PubMedGoogle Scholar
  24. 24.
    Miller WH Jr, Schipper HM, Lee JS, et al.: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893–3903. Timely review of mechanisms of action for an old drug that is gaining acceptance in leukemia therapy.PubMedGoogle Scholar
  25. 25.
    Douer D, Tallman MS: Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005, 23:2396–2410.PubMedCrossRefGoogle Scholar
  26. 26.
    Stallone G, Schena A, Infante B, et al.: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005, 352:1317–1323.PubMedCrossRefGoogle Scholar
  27. 27.
    Recher C, Beyne-Rauzy O, Demur C, et al.: Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527–2534.PubMedCrossRefGoogle Scholar
  28. 28.
    Karp JE, Lancet JE, Kaufmann SH, et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001, 97:3361–3369.PubMedCrossRefGoogle Scholar
  29. 29.
    Akhtar S, Maghfoor I: Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1830–1831.PubMedCrossRefGoogle Scholar
  30. 30.
    Cartron G, Watier H, Golay J, Solal-Celigny P: From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004, 104:2635–2642.PubMedCrossRefGoogle Scholar
  31. 31.
    Leonard JP, Coleman M, Ketas JC, et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003, 21:3051–3059.PubMedCrossRefGoogle Scholar
  32. 32.
    Sievers EL, Larson RA, Stadtmauer EA, et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244–3254. Phase II study demonstrated 30% response rate for gemtuzumab ozogamicin in adults with their first untreated relapse.PubMedGoogle Scholar
  33. 33.
    Arceci RJ, Sande J, Lange B, et al.: Safety and efficacy of gemtuzumab ozogamicin (Mylotarg) in pediatric patients with advanced CD33-positive acute myeloid leukemia. Blood 2005, 106:1183–1188. Epub 2005 May 10.PubMedCrossRefGoogle Scholar
  34. 34.
    Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005, 23:3971–3993. A recent review of the mechanisms and therapeutic value of an important new class of drugs.PubMedCrossRefGoogle Scholar
  35. 35.
    Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429–2440.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Seth J. Corey
    • 1
  1. 1.Section of Pediatric Leukemia and Lymphoma, Division of Pediatrics and Department of LeukemiaUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations